Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz in Madrid, clinical research in Cardiovascular Diseases focuses on arterial hypertension and related risks, with studies designed to explore whether new add-on treatments can improve long-term heart and kidney outcomes.
- Evaluating a new therapy approach for better blood pressure control
- Studying ways to reduce major adverse cardiovascular and renal events
- Assessing treatment effectiveness beyond standard antihypertensive care
This work reflects a practical effort to improve prevention and outcomes in people living with hypertension.
Neoplasms
The site also conducts oncology research in Neoplasms, with attention to extensive-stage small cell lung carcinoma. These trials are aimed at understanding how well new treatment options are tolerated and how they may support care for advanced lung cancer.
- Testing a new cancer therapy alongside standard of care
- Exploring treatment tolerance in advanced small cell lung cancer
- Supporting development of improved options for aggressive lung tumors
Research in this area is centered on finding better ways to manage a fast-moving and difficult-to-treat cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Boehringer Ingelheim Espana S.A.1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of BI 764532 in Combination with Standard of Care for Tolerability in Patients with Extensive-Stage Small Cell Lung Carcinoma | Boehringer Ingelheim Espana S.A., Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG | Phase I | Recruiting | Jan 2024 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 1 | Unknown | 2025-12-10 | 2025-12-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.